BridgeBio Oncology Therapeutics (BBOT) Other Working Capital Changes (2025 - 2026)
BridgeBio Oncology Therapeutics (BBOT) posted Other Working Capital Changes of -$123000.0 for Q1 2026, down 1.65% sequentially from -$121000.0 in Q4 2025.
BridgeBio Oncology Therapeutics (BBOT) Other Working Capital Changes (2025 - 2026) Analysis & Trends
BridgeBio Oncology Therapeutics has reported Other Working Capital Changes for 2 years, with the latest figure at -$123000.0 in Q1 2026.
- Quarterly Other Working Capital Changes changed N/A year-over-year to -$123000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$244000.0 (changed N/A YoY) and the FY2025 annual result came in at -$47000.0, changed N/A from the prior year.
- Other Working Capital Changes retreated to -$123000.0 in Q1 2026 per BBOT's latest filing, from -$121000.0 in the prior quarter.
- Over five years, Other Working Capital Changes peaked at -$121000.0 in Q4 2025 and troughed at -$123000.0 in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | BridgeBio Oncology Therapeutics | 726.38 Mn | 500.67 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -129,000.00 |
| Jun 30, 2026 | -129,000.00 |
| Jun 30, 2026 | -129,000.00 |
| Mar 31, 2026 | -123,000.00 |
| Mar 31, 2026 | -123,000.00 |
| Mar 31, 2026 | -123,000.00 |
| Dec 31, 2025 | -121,000.00 |
| Dec 31, 2025 | -121,000.00 |
| Dec 31, 2025 | -121,000.00 |